title: Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?
abstract: OBJECTIVE
  To evaluate the relation between olfactory impairment (OI) and other impairment domains in Parkinson disease (PD) and the characteristics of OI in patients with certain genotypic characteristics.
  
  
  METHODS
  In 295 nondemented patients with PD and 150 controls with a similar overall age and sex distribution, olfactory function was evaluated with the identification (ID) and discrimination (DIS) tests of the Sniffin' Sticks. In patients, demographic and clinical characteristics were evaluated, and genetic analyses were performed.
  
  
  RESULTS
  Of all patients, 61% had an impaired ID and 43% had an impaired DIS. No significant correlations >0.4 were found between olfactory scores and other demographic or clinical variables. Age and sex accounted for the 22% explained variance of the ID score regression model, whereas age, sex, and disease duration accounted for the 15% explained variance of the DIS score regression model. Parkin and DJ-1 mutation carriers (homozygous or heterozygous compound, n = 6) had normal ID scores. APOE epsilon2 or APOE epsilon4 carriers had no significantly different olfactory scores than noncarriers. The allele distribution of the alpha-synuclein (SNCA)-REP1 polymorphism in groups with an impaired or normal ID or DIS was comparable.
  
  
  CONCLUSIONS
  Olfactory impairment (OI) in Parkinson disease (PD) may be unrelated to other impairment domains of the disease, which may indicate that olfaction is an independent feature of PD. Parkin and DJ-1 mutation carriers had normal identification scores but the number of mutation carriers is too small to draw conclusions. The APOE genotype (APOE epsilon2 or APOE epsilon4 alleles) and SNCA-REP1 polymorphism do not seem to influence olfaction in PD.
authors.affiliation: Department of Neurology, K5Q-92, Leiden University Medical Center, P.O. Box 9600, NL- 2300 RC Leiden, the Netherlands. D.Verbaan@lumc.nl
authors.forename: D
authors.initials: D
authors.lastname: Verbaan
authors.forename: S
authors.initials: S
authors.lastname: Boesveldt
authors.forename: S M
authors.initials: SM
authors.lastname: van Rooden
authors.forename: M
authors.initials: M
authors.lastname: Visser
authors.forename: J
authors.initials: J
authors.lastname: Marinus
authors.forename: M G
authors.initials: MG
authors.lastname: Macedo
authors.forename: Y
authors.initials: Y
authors.lastname: Fang
authors.forename: P
authors.initials: P
authors.lastname: Heutink
authors.forename: H W
authors.initials: HW
authors.lastname: Berendse
authors.forename: J J
authors.initials: JJ
authors.lastname: van Hilten
mesh_terms: D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000235:genetics; D001057:Apolipoproteins E / Q000235:genetics; D016009:Chi-Square Distribution; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D005260:Female; D005838:Genotype; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009154:Mutation; D000857:Olfaction Disorders / Q000209:etiology* / Q000235:genetics*; D010300:Parkinson Disease / Q000150:complications* / Q000235:genetics*; D010641:Phenotype; D012189:Retrospective Studies; D012903:Smell / Q000502:physiology
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D001057:Apolipoproteins E